Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Palatin Technologies Inc. PTN

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$13.2M
$-8.4M
$-13.6M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 13.2M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 13.2 · Net income -8.4
25.0M50.0M-20.0M-40.0M
2009201220152018202120242025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2023 · Operating -501.0% · Net -662.3%
5000%10000%15000%-50000%-100000%-150000%
200920172025
ROE
FY2021 · ROE -109.8%
20%40%-50%-100%-150%
200920172025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -13.6
15M30M-20M-40M
200920172025

Total assetsUSD 8.5M
EquityUSD 6.7M
CashUSD 7.5M
Current ratio4.61×

Equity funds 78% of total assets.

The 17-year record

17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
PTN, 17-year financial record
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.00.00.00.00.0−0.00.00.10.10.10.00.0◌0.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.00.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0◌◌−0.0−0.0−0.00.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B−0.0−0.0−0.0−0.00.0◌0.00.00.00.00.0−0.0−0.0−0.0−0.0−0.0−0.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.00.00.00.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.00.0−0.00.00.0−0.0−0.0−0.0−0.0−0.0◌−0.0
EPS, diluted $−2.96−32.15−101.16◌◌−0.14−0.100.160.120.12−0.33◌◌◌◌◌◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————————
ROE %————−109.8−51.8−24.856.1———−160.6−85.0−168.2−172.3−93.2−19.2
Shares out B0.000.000.020.010.010.230.230.230.200.160.070.060.040.040.030.03◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 65 reconciliationsAUDITED

Reconciled in 17 of the 17 fiscal years we could check. 12 checks were skipped: cost of revenue is not tagged before 2019. Six checks were skipped: the balance sheet is not tagged before 2010. Two checks were skipped: EPS is not tagged before 2009.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inNew Jersey
Fiscal year endsJune 30
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image